Gainor Lewis Berray has filed a Schedule 13G, revealing ownership of 25,300 shares in Clearmind Medicine Inc. This stake represents 4.9% of the company. The filing is significant as it highlights Berray's involvement in the pharmaceutical preparations market, which is experiencing notable developments.

Background

Gainor Lewis Berray is an entity that recently disclosed its holdings in Clearmind Medicine Inc., a company classified under the SIC code for pharmaceutical preparations. Clearmind Medicine operates in a sector that is currently evolving, with various companies vying for market share and innovation.

What the Filing Says

The Schedule 13G filing indicates that Berray holds 25,300 shares of Clearmind Medicine, amounting to 4.9% of the company's total shares. The filing states, "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." This suggests that Berray's investment is not aimed at gaining control over the company.

Impact

This disclosure may affect investor sentiment towards Clearmind Medicine, as it highlights Berray's confidence in the company's potential. With the pharmaceutical preparations industry being highly competitive, such filings can influence how other investors perceive the company's market position and future prospects.

What's Next

The filing does not say what happens next.